Metropolis Network Expansion and Revenue Growth Strategy
Q3 & 9MFY24 Consolidated Profit & Loss Statement
METROPOLIS
The Pathology Specialist
Profit & Loss Statement (Rs. Crs.)
Q3FY24
Q3FY23
Y-o-Y
9MFY24
9MFY23
Y-o-Y
Revenue from Operations
291.1
285.5
2.0%
876.7
865.7
1.3%
Cost of operations
222.5
208.2
663.4
633.8
EBIDTA (before CSR and ESOP)
68.6
77.2
-11.2%
213.3
231.9
-8.0%
EBIDTA (before CSR and ESOP) Margin
23.6%
27.1%
24.3%
26.8%
ESOP & CSR Cost
3.1
4.5
8.5
8.2
Reported EBIDTA
65.5
72.7
-10.0%
204.8
223.6
-8.4%
Reported EBIDTA (%)
Depreciation
Other Income
22.5%
25.5%
23.4%
25.8%
25.0
23.1
68.1
65.8
2.3
6.8
6.6
14.0
EBIT
42.8
56.4
-24.2%
143.4
171.8
-16.6%
Finance Cost
5.9
8.4
19.2
26.2
Profit Before Tax
36.9
48.0
-23.2%
124.2
145.6
-14.7%
Current Tax
9.6
12.1
32.2
35.7
Profit After Tax
27.3
35.9
-23.9%
91.9
109.9
-16.4%
PAT Margin
9.4%
12.6%
10.5%
12.7%
19View entire presentation